Key Takeaway
Meta-analysis found NAC significantly improves symptoms across major mental disorders including schizophrenia, bipolar, and depression, supporting its role as a transdiagnostic psychiatric treatment
Summary
This systematic review and meta-analysis evaluated NAC for major mental disorders across multiple diagnostic categories. The study found NAC significantly improved various psychiatric symptoms, supporting its potential as a broad-spectrum treatment adjunct in psychiatry. The glutathione precursor mechanism may explain transdiagnostic benefits through oxidative stress reduction.
Methods
Systematic review and meta-analysis of RCTs evaluating NAC across major mental disorders including schizophrenia, bipolar disorder, depression, and substance use disorders. Multiple databases searched. Published in Acta Psychiatrica Scandinavica.
Key Results
NAC showed significant improvements across multiple psychiatric conditions. Benefits observed for schizophrenia symptoms, depressive episodes in bipolar disorder, and depression severity. Transdiagnostic mechanism suggested through oxidative stress and glutamate modulation.
Limitations
Heterogeneous diagnostic categories combined. Variable NAC doses and treatment durations. Most trials were adjunctive designs. Moderate overall quality of evidence. Different outcome measures across conditions limit direct comparisons.